Dividend Stock Portfolio for Income: 15 Stocks to Invest In

In this article, we will take a look at the Dividend Stock Portfolio for Income: 15 Stocks to Invest In.

Growth often takes center stage in an investing strategy. Still, for many investors, income can matter just as much, sometimes even more. Getting there takes planning and a clear approach to how assets are allocated.

Matthew Diczok, head of fixed income strategy in the Chief Investment Office for Merrill and Bank of America Private Bank, said, “Investing for income requires you to think differently about your assets, especially in volatile interest-rate environments.” Dividend-paying stocks, in his view, are a key part of that strategy. He explained that these stocks can provide a steady stream of income through regular payouts. Prices may move up or down based on a company’s outlook, but the income component remains. At the same time, there is still room for capital appreciation, which can matter over a full market cycle.

He also pointed out that if the market begins to broaden beyond a small group of dominant names, high-quality dividend stocks could benefit. For many investors, he suggested a practical approach. Using ETFs and mutual funds can be a more cost-efficient way to build a fixed-income or dividend-focused portfolio. These vehicles offer diversification across multiple securities and can help keep transaction costs lower.

Given this, we will take a look at some of the best stocks for a dividend stock portfolio.

Photo by Sharon McCutcheon on Unsplash

Our Methodology:

For this list, we first used a stock screener to pick companies that have stable dividend histories and narrowed down our options to companies with dividend yields of around 1%, as of March 26, demonstrating robust financial standings and consistent cash flow, which are indicative of their ability to sustain reliable dividends for passive income. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

15. Cintas Corporation (NASDAQ:CTAS)

Dividend Yield as of March 26: 1.04%

On March 26, UBS Group AG lowered its price recommendation on Cintas Corporation (NASDAQ:CTAS) to $228 from $235. It reiterated a Buy rating on the stock. The firm noted that Cintas reported 8.2% organic growth, even though payroll growth remained limited. Earnings per share came in line with expectations but did not exceed them, which the analyst suggested could be tied to the timing of SG&A expenses. At the same time, the company raised its full-year outlook. With EBIT margins continuing to improve and the stock trading at a lower multiple, the analyst sees a compelling setup, especially when viewed against the longer-term potential of the pending UniFirst Corporation deal.

During the fiscal Q3 2026 earnings call, management said it expects full-year revenue to land between $11.21 billion and $11.24 billion. That points to growth of roughly 8.4% to 8.7%. Adjusted diluted EPS is projected in the range of $4.86 to $4.90, suggesting growth of about 10.5% to 11.4%. Management also clarified that this EPS outlook excludes one-time costs tied to the UniFirst acquisition. These costs are expected to reduce diluted EPS by about $0.03 to $0.04 for the full year. CFO Garula indicated that most of these expenses should show up in the fourth quarter and are not expected to materially affect third-quarter results.

The guidance assumes stable foreign exchange rates. It also reflects a projected net interest expense of around $101 million and an effective tax rate of 20%.

Cintas Corporation (NASDAQ:CTAS) focuses on developing uniform programs using fabric. It serves businesses of various sizes, mainly across the United States, as well as in Canada and Latin America. The company operates through two segments: Uniform Rental and Facility Services, and First Aid and Safety Services.

14. Nucor Corporation (NYSE:NUE)

Dividend Yield as of March 26: 1.34%

On March 26, UBS Group analyst Andrew Jones upgraded Nucor Corporation (NYSE:NUE) to Buy from Neutral and raised the price target to $190 from $184. The analyst pointed to the recent “excessive correction” as a buying opportunity. He told investors that US steel producers appear “largely insulated” from the Iran conflict. He also said the setup for Nucor looks favorable, citing limited direct exposure to energy and ongoing project growth supported by a stronger pricing and volume backdrop tied to federal support.

On March 25, KeyBanc Capital Markets initiated coverage on Nucor with a Sector Weight rating. The firm said it is revisiting its 2026 outlook for US carbon steel companies following recent due diligence and its Q1 proprietary Sheet on the Street survey. Its estimate revisions for Q1 and full-year 2026 came in mixed. Even so, it maintained its view that the sector is seeing clear year-over-year improvement in profitability, driven by better pricing and spreads.

Nucor Corporation (NYSE:NUE) manufactures steel and steel products and operates facilities across the United States, Canada, and Mexico. The company also produces and sources ferrous and non-ferrous materials, mainly for use in its own steel operations. It runs its business through three segments: steel mills, steel products, and raw materials.

13. Aflac Incorporated (NYSE:AFL)

Dividend Yield as of March 26: 2.26%

On March 26, Keefe Bruyette & Woods re-initiated coverage of Aflac Incorporated (NYSE:AFL) with a Market Perform rating and a $113 price target. The analyst said the life insurance sector shows a mixed fundamental picture. Companies have reduced liability tail risk and improved free cash flow conversion, while also benefiting from stronger growth. At the same time, the note pointed to rising competition, higher investment leverage, increasing balance sheet complexity, and macro tailwinds that may not last.

During the Q4 2025 earnings call, Senior EVP and CFO Max Broden said most of the company’s previously issued 2026 guidance remained in place, with only a few adjustments. For Aflac Japan, he said, underlying earned premiums are now expected to decline by about 1% to 2% in 2026. The expense ratio is projected in the 20% to 23% range. He also noted that the benefit ratio in Japan is expected to fall between 60% and 63%, with a pretax profit margin of 33% to 36%.

Looking at the US segment, Broden said the company still expects net earned premium growth at the lower end of the 3% to 6% range. He added that the benefit ratio for 2026 is projected between 48% and 52%, while the expense ratio is expected to come in between 36% and 39% as the company continues to expand its newer business lines.

Aflac Incorporated (NYSE:AFL) provides financial protection through its subsidiaries in the United States and Japan. Its core business centers on supplemental health and life insurance products.

12. Union Pacific Corporation (NYSE:UNP)

Dividend Yield as of March 26: 2.30%

On March 26, RBC Capital Markets lowered its price recommendation on Union Pacific Corporation (NYSE:UNP) to $273 from $280. It reiterated an Outperform rating on the shares.  The update came as part of a broader research note previewing Q1 results for Class I railroads. The firm raised its Q1 EPS estimate by $0.06 to $2.90, pointing to volumes that are running well ahead of consensus expectations. At the same time, the analyst noted there is an increased risk around deal approvals.

On March 19, Evercore ISI upgraded Union Pacific to Outperform from In Line and lifted its price target to $262 from $260. The analyst said that even though merger-related “trading purgatory” may still be in place, the company is operating “at an elite level.” That performance is showing up in strong volume growth and solid margins, while the stock still trades at a discount to most peers. The firm added that the merger deal is either going to fall apart, which it views as “highly unlikely,” or the stock will be seen as “a premier growth Industrials equity deserving of a premium multiple” once there is better visibility on closing. The analyst described the stock as a “heads you win, tails you win” idea within the group.

Union Pacific Corporation (NYSE:UNP), through its main operating unit, Union Pacific Railroad Company, connects more than 23 states across the western two-thirds of the United States by rail. It plays a key role in the global supply chain.

11. Gilead Sciences, Inc. (NASDAQ:GILD)

Dividend Yield as of March 26: 2.38%

On March 23, The Wall Street Journal reported that Gilead Sciences, Inc. (NASDAQ:GILD) plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion. The company also intends to develop the acquired assets in collaboration with Galapagos NV. Under the deal terms, Gilead would purchase all outstanding equity of Ouro for about $1.68 billion in cash upfront, payable at closing, along with up to $500 million in contingent milestone payments.

Gilead also said it is in discussions with Galapagos regarding a potential research-and-development partnership tied to these assets. As part of the arrangement, Galapagos would fund half of the upfront payment and half of any milestone obligations. It would also take on most of Ouro’s operating assets and employees. Gilead currently holds roughly a 25% stake in Galapagos and already has an agreement that provides access to its drug-discovery platform.

Gilead noted that the acquisition would strengthen its inflammation portfolio. It would add gamgertamig, which has shown efficacy after a single treatment cycle in severe antibody-mediated orphan diseases, including autoimmune hemolytic anemia and immune thrombocytopenia, in ongoing Phase 1/2 studies.

Gamgertamig has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration and is expected to move into late-stage studies in 2027, according to Gilead. The company said it plans to co-develop the asset with Galapagos, with both firms sharing trial costs. Gilead would retain most global commercialization rights and pay royalties of 20% to 23%.

Galapagos will also gain access to $500 million outside the 2019 agreement to support independent research. Gilead’s CMO, Dietmar Berger, described the move as part of the company’s effort to expand treatments for autoimmune diseases.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company focused on developing medicines to prevent and treat serious diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation.

10. QUALCOMM Incorporated (NASDAQ:QCOM)

Dividend Yield as of March 26: 2.70%

On March 26, Bernstein Research downgraded QUALCOMM Incorporated (NASDAQ:QCOM) to Market Perform from Outperform. It cut its price target to $140 from $175. The firm pointed to memory-related headwinds, noting that higher prices are having a “deleterious effect” on overall smartphone shipments. The analyst told investors that consensus estimates for Qualcomm “now appear much too high.” Bernstein also said the company’s “potential narrative tailwinds” from its buyback program and upcoming data center event are unlikely to offset weaker smartphone demand. It also flagged risk tied to the expiration of the Apple license agreement in about a year.

On March 17, Qualcomm announced a $20 billion stock buyback program, aiming to take advantage of a sharp decline in its share price. The drop has been linked to a global memory supply crunch, which is expected to slow handset production. The new authorization comes on top of the company’s existing $2.1 billion buyback plan. Qualcomm also said it is raising its quarterly cash dividend by more than 3% to $0.92 per share from $0.89.

QUALCOMM Incorporated (NASDAQ:QCOM) develops and commercializes core technologies for the wireless industry. Its work spans 3G, 4G, and 5G connectivity, along with high-performance, low-power computing, including on-device artificial intelligence.

9. Merck & Co., Inc. (NYSE:MRK)

Dividend Yield as of March 26: 2.84%

On March 25, RBC reiterated an Outperform rating on Merck & Co., Inc. (NYSE:MRK) with a $142 price target. After the company held a conference call to discuss its proposed acquisition of Terns Pharmaceuticals (TERN), RBC Capital Markets analyst Trung Huynh said the “prevailing feedback” from investors has been one of disappointment. He noted that investors questioned the deal premium and why Terns would agree to what was described as a “modest premium” for a “high-probability asset.”

At the same time, Merck received positive comments. Investors viewed the company “as a savvy capital allocator addressing their upcoming patent cliff.” Still, the firm said some investors do not see this as the final outcome. There is an expectation that competing bidders could emerge or that shareholders may reject the deal altogether.

Merck & Co., Inc. (NYSE:MRK) is a global healthcare company that develops and delivers treatments through prescription medicines, including biologic therapies, vaccines, and animal health products. Its Pharmaceutical segment focuses on human health drugs and vaccines.

8. American Electric Power Company, Inc. (NASDAQ:AEP)

Dividend Yield as of March 26: 2.95%

On March 23, Morgan Stanley raised its price recommendation on American Electric Power Company, Inc. (NASDAQ:AEP) to $137 from $133. It reiterated an Overweight rating on the shares. The firm said it is revisiting its price targets across regulated and diversified utilities and IPPs in North America. It pointed out that utilities outperformed the S&P 500 in February, which stood out given the broader market backdrop. Recent discussions in the sector sounded constructive. Companies talked about steady growth opportunities, better visibility on load demand, and continued momentum in signing data center-related deals.

On the earnings side, during the Q4 2025 call, American Electric said it is sticking with its 2026 operating EPS guidance of $6.15 to $6.45. It also left its longer-term outlook unchanged, still expecting earnings to grow 7% to 9% annually from 2026 through 2030. Management said the $72 billion five-year capital plan is based on an earlier estimate of 28 gigawatts of incremental demand. Within that, it pointed to $5 billion to $8 billion of generation and transmission projects that are already confirmed or have support in place.

American Electric Power Company, Inc. (NASDAQ:AEP) operates as a public utility holding company. Its operating units handle generation, transmission, and distribution, serving more than five million customers across multiple U.S. states, including Arkansas, Indiana, Kentucky, Louisiana, Michigan, Ohio, Oklahoma, Tennessee, Texas, Virginia, and West Virginia.

7. Mondelez International, Inc. (NASDAQ:MDLZ)

Dividend Yield as of March 26: 3.43%

On March 25, Rothschild & Co Redburn downgraded Mondelez International, Inc. (NASDAQ:MDLZ) to Neutral from Buy. It lowered the stock’s price target to $55 from $71. The analyst said the company is dealing with “numerous near-term threats.” These include softer volumes, more intense competition in European chocolate, a slow U.S. biscuit category, and weaker growth across emerging markets. The firm also noted that addressing these issues will likely require reinvestment in pricing strategies and advertising. That could limit the benefit Mondelez would otherwise see from easing cocoa prices. Based on this view, Rothschild reduced its estimates and downgraded the stock.

Earlier, on March 16, Morgan Stanley took a more constructive stance. The firm raised its price recommendation on Mondelez to $70 from $66. It reiterated an Overweight rating. The analyst argued that the market is placing too much emphasis on pricing rollback risk, while not fully accounting for the earnings recovery expected from cocoa normalization starting in the second half of 2026 and building into 2027. Morgan Stanley also named the stock a Top Pick.

Mondelez International, Inc. (NASDAQ:MDLZ) operates as a snack company. Its core business centers on chocolate, biscuits, and baked snacks, along with additional categories such as gum and candy, cheese and grocery, and powdered beverages.

6. Kinder Morgan, Inc. (NYSE:KMI)

Dividend Yield as of March 26: 3.45%

On March 26, Scotiabank raised its price recommendation on Kinder Morgan, Inc. (NYSE:KMI) to $32 from $31. It kept a Sector Perform rating on the shares.  The analyst said the company was impacted more by January’s winter weather than by supply disruptions in the Middle East. Management also indicated that the Iranian conflict has had an essentially neutral effect so far.

A couple of days earlier, on March 24, Jefferies analyst Julien Dumoulin-Smith raised the price goal on Kinder Morgan to $36 from $31 and maintained a Hold rating. The firm said the investment case will be “increasingly defined” by how well the company executes on its projects and converts its backlog. After the recent rally in the stock, the analyst noted that further upside will likely depend more on execution than on any expansion in valuation multiples.

Kinder Morgan, Inc. (NYSE:KMI) operates as an energy infrastructure company. It owns interests in or runs about 79,000 miles of pipelines and 139 terminals. Its Natural Gas Pipelines segment includes interstate and intrastate pipelines, storage systems, gathering networks, and processing and treating facilities.

Click to continue reading and see the Dividend Stock Portfolio for Income: 5 Stocks to Invest In

Disclosure: None. Follow Insider Monkey on Google News.